Abridge vs Nabla (2026)
This is the most asked head to head in ambient documentation, and the two companies are running different plays. Abridge is the enterprise reference standard: Best in KLAS for Ambient AI in 2025 and 2026, the largest independent peer reviewed study in the category with 1,306 clinicians at Kaiser Permanente published in NEJM AI, and the deepest Epic integration in the index. Nabla's edge is breadth: the widest EHR footprint in the category, spanning Epic, athenahealth, Oracle Health, NextGen, and Greenway. If your failure mode is an Epic health system that needs auditable evidence and native workflow depth, start with Abridge. If your failure mode is a mixed EHR environment that one contract has to cover, start with Nabla, and confirm its data training default and BAA tier before deployment. Neither publishes pricing.
- The evidence bar decides it for you: the largest independent peer reviewed study in the category, 1,306 clinicians at Kaiser Permanente published in NEJM AI, corroborated by Best in KLAS for Ambient AI in both 2025 and 2026, which is buyer survey based rather than vendor asserted.
- Compliance needs an audit trail, not trust: Linked Evidence maps every part of a generated note back to the source audio so a clinician can verify any sentence against what was said before signing.
- You are an Epic organization buying workflow depth: Abridge is embedded natively across Haiku, Canto, and Hyperdrive with bidirectional note sync, extending into structured orders and real time prior authorization.
- You run a mixed EHR estate: integrations span Epic, athenahealth, Oracle Health, NextGen, and Greenway, the widest footprint in the category, which means one scribe contract instead of several.
- Your deployment profile matches its base: reported across more than 85,000 clinicians at over 150 organizations, weighted toward hospital systems, emergency departments, and multi provider groups.
- You want published efficiency figures tied to peer review: the vendor attributes roughly 55 percent of users saving at least an hour a day and a 27 percent reduction in burnout to a published NEJM study.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Abridge and Nabla are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Abridge | Nabla |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2018 | 2018 |
| Headquarters | Pittsburgh, Pennsylvania | Paris, France |
| Website | abridge.com | nabla.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Abridge its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model Supply Chain Disclosure. Set against Nabla, Abridge grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Nabla its top capability grade on several axes, including AI Centrality, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Set against Abridge, Nabla grades higher on AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Abridge or Nabla?
On the axes where the AI Health Index separates them, Abridge grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure, and Nabla grades higher on AI Safety and PHI Stewardship. Abridge leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Abridge and Nabla differ most?
The widest separation the AI Health Index records between Abridge and Nabla is on Autonomy and Oversight Model, where Abridge grades A and Nabla grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Abridge and Nabla grade the same?
The AI Health Index grades Abridge and Nabla the same on several axes, including AI Centrality, Clinical and Operational Evidence and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Deployment counts, language totals, and efficiency figures for both vendors are vendor published and have not been independently validated by this index. Abridge's evidence grade reflects the scale and venue of the Kaiser Permanente study, not a re verification of its findings.
Two Nabla capability records carry procurement caveats: session data is reported as used for model training by default, and the free tier reportedly does not include a Business Associate Agreement; confirm both contractually before deployment. Neither company publishes pricing. Abridge is enterprise only with a third party estimate near $2,500 per clinician per year recorded as an estimate; Nabla has moved off previously published tiers toward a contract sales motion.